Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
Holding RCKT?
Track your performance easily
RCKT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.76 - $32.53
Previous Close$12.02
Volume1.39M
Average Volume (3M)1.05M
Market Cap
$1.25B
Enterprise Value$1.04B
Total Cash (Recent Filing)$235.66M
Total Debt (Recent Filing)$25.64M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Mar 06, 2025EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding91,157,085
10 Day Avg. Volume1,426,623
30 Day Avg. Volume1,051,461
Standard Deviation0.18
R-Squared0.09
Alpha-0.00131
Financial Highlights & Ratios
Price to Book (P/B)3.32
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-454.07
Enterprise Value/Ebitda-4.16
Forecast
1Y Price Target
$46.36Price Target Upside285.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Rocket Pharmaceuticals News
PremiumCompany Announcements
Rocket Pharmaceuticals Advances Genetic Therapies Pipeline
PremiumCompany Announcements
Rocket Pharmaceuticals Advances Danon Disease and PKD Studies
Bulls Say, Bears Say
Bulls Say
Clinical DataRocket Pharma's RP-A501 treatment for Danon disease has shown durable and clinically meaningful improvements in all key disease metrics, suggesting it could become a paradigm-shifting therapy.
Investor ConfidenceThe updated long-term data for RP-A501 has de-risked the ongoing pivotal study, offering greater confidence to investors about the program's success and supporting the potential for strong commercial interest.
Regulatory ProgressRocket Pharma is aligned with the FDA on co-primary endpoints for the pivotal Phase 2 study of RP-A501, reinforcing confidence in the treatment's path forward.
Bears Say
Financial PerformanceUpdating the model for the offering has resulted in a lower price target, now set at $40.
Regulatory DelaysApproval of Kresladi CRL in leukocyte adhesion deficiency type I has been delayed, impacting the stock's prospects.
Research And DevelopmentThe pivotal study for RP-L301 has been postponed, indicating potential setbacks in the development pipeline.
---
Ownership Overview
17.93% Insiders
23.14% Mutual Funds
40.30% Other Institutional Investors
7.48% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCKT FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $11.76 and its highest was $32.52 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Currently, no data Available
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is Mar 06, 2025 which is in 74 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.75 by $0.04.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -$0.73.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 104,357,086 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.75. Following the earnings report the stock price went up 1.159%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Among the largest hedge funds holding Rocket Pharmaceuticals’s share is Maverick Capital ltd. It holds Rocket Pharmaceuticals’s shares valued at 76M.
---
Rocket Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.36 (285.69% Upside)
$46.36 (285.69% Upside)
Blogger Sentiment
Bullish
RCKT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 273.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $302.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.41%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
-34.25%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
RCKT Stock 12 Month Forecast
Average Price Target
$46.36
▲(285.69% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Sangamo Biosciences
―
Best Analysts Covering RCKT
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+15.01%
reiterated a buy rating last month
Copying Greg Harrison's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +15.01% per trade.
---